 Shares of Oramed Pharmaceuticals Inc. ORMP, 5.78 plunged 72 in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled trial compared Orameds treatment to placebo to see if it improved glycemic control in patients with type 2 diabetes. 